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Abstract: A rare case of external genital condylomata acuminatum with Graves’ disease was reported. The cauliflower 
warts were observed on glans penis and foreskin of a 40-year-old man, who had typical Graves’ symptoms. After 
combining treatment of laser, intramuscular injection interferon, and orally administered Acyclovir or Tamciclovir 
tablets, Amoxicilline capsules or phenoxy mephyl penicillin potassium tablets, vitamin C and vitamin B1 of multiple 
courses (weeks), the condylomata acuminatum recurred, the warts grew again, and Graves’ disease worsened. However, 
after integrated treatment of laser, orally administered transfer factor, antibiotics and vitamins of three courses, the 
patient recovered fully and Graves’ symptoms alleviated. The venereal warts have not recurred within six months. 
Keywords: Condyloma Acuminatum, Graves’ disease, Laser, Interferon, Antibiotic, Recurrence, Transfer Factor. 
 
INTRODUCTION 
            Condyloma acuminatum or acuminate wart or 
venereal wart is a genital lesion caused by human 
papillomavirus (HPV) infection, one of the most 
common sexually transmitted diseases [1-3]. Generally, 
genital warts can occur in the vagina and on the cervix 
in female. However, in men, growths on the penis tend 
to be very flat and are sometimes hard to see [2]. 
Current forms of treatments for condylomata 
acuminatum include surgical treatment (i.e. laser 
ablation, electro surgery scissors excision and 
curettage), cryotherapy, podophyllum resin, 
podophilox, trichloroacetic acid, loop electrosurgical 
therapy, interferon, and others [1-3]. This case was 
reported because of its rarity and speciality: condyloma 
acuminatum with Graves’ disease, challenge of 
treatment for the patient and non-predictableness of the 
treatment effect. Therefore, the case report could 
provide valuable information to physicians, nurses, 
health professionals, epidemiologists, clinics, hospitals 
and medical agencies for more effective treatment, 
control and prevention of condylomata acuminatum.   
 
CASE REPORT  
          A 40-year-old male worker was diagnosed 
external acuminate wart in the district hospital, Beibei, 
Chongqing, China. The cauliflower warts grew on his 
glans and foreskin. Meanwhile, the patient was 
diagnosed definitely Graves’ disease in the hospital 
according to his typical Graves’ symptoms and results 
of laboratory test (blood test) for checking thyroid 
hormone levels. Firstly, the patient was treated with 
carbonized (CO2) laser and intramuscular injection 
interferon (3,000,000 units/time, one time/day) of two 
courses (two weeks) in the hospital. Nevertheless, after 
two weeks, the dermal surface of the lesion was 
infected and the warts grew again. One month later, the 
warts grew fully on glans and prepuce, and merged the 
lump (3x4x0.5cm). Then, the patient was treated with 
laser (depth: 1.5-2mm under the bottom of warts), 
intramuscular injection interferon (3,000,000 units/time, 
one time/day), and oral Acyclovir tablets of (0.2 
mg/time, five times/day) and Amoxicilline capsules 
(0.5mg/time, three times/day) of two courses (two 
weeks). After three weeks, the patient’s condition had 
still not been improved, and the warts enlarged. Though 
the patient was treated again with laser, injection 
interferon, oral Tamciclovir tablets (0.25 mg, one 
time/eight hours), phenoxymephylpenicillin potassium 
tablets (0.5mg/time, three times/days), vitamin C 
(100mg/time, three times/day) and vitamin B1 (10 
mg/time, three times/day) of two courses (two weeks), 
the new warts grew again on glans penis except 
foreskin. Meanwhile, the patient presented more 
marked Graves’ symptoms: more bulging eyes, larger 
goiter and thicker skin, which demonstrated that 
Graves’ disease of the patient worsened. However, after 
therapy of laser, oral transfer factor, antibiotics and 
vitamins of three courses (10 mg/time, two times/day), 
no new warts grew on penis of the patient, and Graves’ 
disease alleviated. After six months, with being 
examined once a month within six months, venereal 
warts have not recurred again.     
 
DISCUSSION   
          The carbon dioxide laser vaporization is a simple, 
safe and effective therapeutic approach for the 
treatment of human papillomavirus warts and genital 
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condylotama [4, 5]. Laser therapies have been used 
broadly in treatment for patients with strawberry 
angioma of infancy, decorative tattoos, genital 
condylomata and warts, and showed good effects [6], 
except that less data reveal that treatment of recalcitrant 
condylomata acuminata with the carbon dioxide laser 
did not offer any advantages over traditional surgery, 
including electrocautery [3, 7].  Notwithstanding, the 
laser therapy for the patient could not eradicate 
completely acuminate wart, the combining treatments 
with laser ablation are essential. Many of data show that 
the applications of other favorable safety profiles or 
agents are also effective for treatment and prevention of 
condyloma acuminate, such as podophyllotoxin and 
imiquimod [3, 6, 8], Autogenous vaccine [9], 
intraurethral instillation and 5-fluorouracil solution [3, 
10], Trichloroacetic acid [3], Chinese medicine 
Keyouling [11], salicylic acid and dinitrochlorobenzen 
[12], cidofovir [3, 13], photodynamic therapy with 
topical 5-aminolevulinic acid [14], microwave therapy 
combined with interleukin-2 [15], and others.     
         
   The interferons (IFNs) are one of the body's 
natural defensive responses to
 
such foreign components 
as microbes, tumors, and antigens. The clinical uses
 
of 
IFNs with other combination therapies, such as 
chemotherapy, radiation, laser, surgery, hyperthermia, 
or hormones, are effective for treatment of infectious 
diseases [16]. IFNs play important roles in reducing 
tumor growth and modulating immune responses and 
have been widely used in the
 
treatment of neoplastic, 
viral, and autoimmune diseases [17]. Some of data 
show that interferons have positive effects on treatment 
of infection with human papilloma virus, such as 
condyloma acuminate [18-20]. Moreover, the integrated 
therapy using laser surgery, electrosurgery or 
cryosurgery followed by the intralesional administration 
of interferon appears to enhance treatment effects [20]. 
In particular, the direct injection of interferon alpha-2b 
into genital warts appears to be an effective and fairly 
well-tolerated form of therapy [20, 21], and has 
significant activity in the treatment of genital warts [22, 
23]. 
         
However, the treatment of interferon for the 
patient in the case report has not achieved the 
significant effect and the desired result, and led to 
worsening of Graves’ disease. It has been known that 
adverse effects of interferon treatment include systemic 
and organ-specific pathological changes; many of them 
are the consequences of
 
immune enhancement or 
immune deregulation induced by interferon itself [24]. 
Meanwhile, Recurrence of condylomata acuminata is 
not prevented by systemically administered interferon 
[25]. On the other hand, some of studies indicate that 
the use of interferons might result in thyroid 
dysfunction in a variety of ways and induce thyroid 
disease [26-28], because interferons may have direct 
effects on the
 
thyroid gland by modulating the aberrant 
expression of major
 
histocompatibility antigens on 
thyroid cells [29] and favoring
 
a cytokine 
microenvironment, which are able to lead to the 
immunemediated damage of thyroid tissue [30]. Most 
of data reveal that primary hypothyroidism associated 
with interferon therapy [31- 33]. Risk factors for 
developing thyroid dysfunction with interferon 
treatment are female sex, underlying malignancy or 
hepatitis C, higher doses of IFN for longer durations 
[33]. Although the development of thyroid disease does 
not seem to be related
 
to the dose of interferon [34], the 
duration of interferon treatment
 
has been related to the 
occurrence of thyroid dysfunction [35]. Some of clinical 
data present that interferon treatment may also induce 
Graves’ hyperthyroidism [36-38], which may occur 
even
 
after a transient phase of destructive thyrotoxicosis 
[39]. Though
 sporadic cases of Graves’ ophthalmopathy 
have been described
 
in patients treated with interferon 
[40], most of patients developing Graves’ 
hyperthyroidism do not
 
have signs of autoimmune 
ophthalmopathy [36].  
 
         According to the negative effect of interferon 
treatment on the patient, the clinical use of transfer 
factor was recommended in the treatment of the patient 
suffering acuminate wart with Graves’ disease. Transfer 
factor (TF) is an immunomodulator active substance. It 
could decrease the number of inflammatory cells and 
the severity of the symptoms of atopic dermatitis [41], 
and activate the proliferation of lymphocytes and 
splenocytes [42]. Therefore, it is an efficacious agent 
for immunotherapy of certain viral and fungal 
infections [43, 44]. The reports of efficacy of
 
transfer 
factor in immunodeficiency states and chronic 
infectious diseases,
 
as well as its lack of toxicity, have 
spurred clinical trials of transfer factor therapy
 
in 
human malignant diseases [45]. Transfer factor has 
been used to treat chickenpox, chronic active hepatitis 
and AIDS [46], and may be beneficial in some patients 
with Behcet's
 
syndrome [47]. In particular, transfer 
factor treatment could lead to spontaneous regression of 
human warts [48].  
 
Furthermore, transfer factor therapy may be 
used as a choice of treatment for preventing genital or 
labial herpes recurrences [49]. The clinical reports show 
that the combining application of transfer factor, 
antibiotic and carbon dioxide laser is effective and safe 
for treatment of condyloma acuminatum [50], and the 
treatment effect of transfer factor for acuminate wart is 
equal to or superior to that of interferon, but 
administered more easily [51-53]. This case report 
reveals that transfer factor can be used effectually in the 
treatment of condyloma acuminatum and the 
impediment of its reversion, and does not conduce to 
other negative effect on Graves’ disease.   
 
CONCLUSION  
         When the interferon therapies for viral infectious 
diseases, especially for condyloma acuminatum, do not 
present significant and desired effects, and/or bring 
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negative affection, other effective substitutive 
immunotherapy agent(s), such as transfer factor and 
others, should be used in the clinical treatment for the 
sexually transmitted disease. The patients receiving 
interferon therapy should be closely monitored for the 
possible development of thyroid dysfunction and other 
side effects [54]. Transfer factor may be a better choice 
of treatment for acuminate wart, albeit its doctoring 
effects for epidemic venereal diseases need to be 
studied further. The acceptable and practicable 
integrated approaches for treatment of venereal warts 
should be implemented in improvement of therapies, 
declining of negative effects and palliation of 
symptoms, lessening of lesion, and control and 
prevention of recurrence.   
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